What is Magenta?
Magenta specializes in the development of advanced medical devices, with a particular focus on the Elevate percutaneous Left Ventricular Assist Device (pLVAD). This cutting-edge technology is engineered to provide temporary circulatory support for patients undergoing high-risk coronary interventions and those experiencing cardiogenic shock. The company's mission is to equip healthcare professionals with essential tools to enhance patient outcomes in critical cardiac scenarios. Magenta's innovative solutions are targeted for deployment in medical facilities equipped to handle severe cardiovascular conditions, aiming to bridge the gap in acute cardiac care.
How much funding has Magenta raised?
Magenta has raised a total of $160M across 2 funding rounds:
Other Financing Round
$55M
Other Financing Round
$105M
Other Financing Round (2023): $55M with participation from OrbiMed and New Enterprise Associates
Other Financing Round (2024): $105M led by Novo Holdings, Viking Global Investors, and RA Capital Management
Key Investors in Magenta
Novo Holdings
Novo Holdings is a Danish investment company wholly owned by the Novo Nordisk Foundation, focusing on investments within the life sciences sector.
Viking Global Investors
Viking Global Investors is a global investment firm that specializes in research-intensive, long-term investments across various industries and geographies, utilizing fundamental analysis.
RA Capital Management
RA Capital Management is a multi-stage investment manager concentrating on public and private healthcare and life science companies, including those in drug development, medical devices, and diagnostics.
What's next for Magenta?
With the recent influx of major enterprise-level funding and a significant strategic investment, Magenta is poised for accelerated growth and market expansion. This substantial backing is expected to fuel further research and development, enhance manufacturing capabilities, and broaden the commercialization of its pLVAD technology. The company's strategic focus will likely involve scaling operations to meet increasing demand and solidifying its position as a leader in temporary cardiac support devices. Continued investment in innovation and strategic partnerships will be key to Magenta's trajectory in improving patient outcomes in critical cardiac care.
See full Magenta company page
